Open AccessOlanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants
Author(s) -
Xue Xia,
Seok-Kweon Yun,
Xiaojie Yu,
Fan Qiang,
Jinjin Tang,
Xu Chen
Publication year - 2018
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000009786
Subject(s) - olanzapine , haloperidol , brief psychiatric rating scale , medicine , adverse effect , schizophrenia (object oriented programming) , clinical global impression , amphetamine , psychiatry , anesthesia , psychosis , alternative medicine , pathology , dopamine , placebo
Background: This study aimed to compare olanzapine and haloperidol efficacies in the treatment of acute psychiatric symptoms due to amphetamine-type stimulants (ATSs). Methods: The Zelen II design method was used; 124 patients with acute mental disorders due to amphetamine were randomly divided into olanzapine group (n = 63) and haloperidol group (n = 61). Then, a 4-week open-label medical therapy was performed. Clinical Global Impression Scale Item 2 was employed to evaluate the onset time; meanwhile, Brief Psychiatric Rating Scale (BPRS) was used at baseline and at posttreatment weeks 1, 2, and 4. Moreover, adverse reactions during the treatment were recorded. Results: Onset time in the olanzapine group was significantly earlier than in the haloperidol group; BPRS scores in the olanzapine group were significantly lower than haloperidol group values at 1 and 2 weeks of treatment. The overall effective rates had no statistically significant difference. Conclusion: Short-term olanzapine and haloperidol treatments had equivalent efficacies in the treatment of acute symptoms of mental disorders due to ATSs; however, olanzapine administration resulted in relatively earlier disease onset, with less adverse reactions.